Literature DB >> 7105396

The hazard of mould hyposensitization in children with asthma.

P H Kaad, P A Ostergaard.   

Abstract

Of thirty-eight children, who were immunized with mould extracts, seven (19%) were withdrawn from hyposensitization due to serious side-effects clinically consistent with a type III reaction. These seven children exhibited a two- to four-fold increase in circulating precipitating-antibodies to the injected extracts, and had shown a slight increase in precipitating antibodies to the mould extracts used before hyposensitization. A further fourteen patients, also hyposensitized with mould extracts but without side effects did not develop precipitating antibodies. It is suggested that hyposensitization with mould extracts may be hazardous in children who may have a primary "immune imbalance' with a risk of provoking type III reactions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105396     DOI: 10.1111/j.1365-2222.1982.tb02534.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  6 in total

Review 1.  Immunotherapy for mold allergy.

Authors:  H J Malling
Journal:  Clin Rev Allergy       Date:  1992

Review 2.  Immunotherapy of mold allergy: A review.

Authors:  A Bozek; K Pyrkosz
Journal:  Hum Vaccin Immunother       Date:  2017-05-08       Impact factor: 3.452

Review 3.  Mold allergens in respiratory allergy: from structure to therapy.

Authors:  Teresa E Twaroch; Mirela Curin; Rudolf Valenta; Ines Swoboda
Journal:  Allergy Asthma Immunol Res       Date:  2015-03-11       Impact factor: 5.764

4.  Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study.

Authors:  Luis Prieto; Ricardo Palacios; Dulce Aldana; Anna Ferrer; Carmen Perez-Frances; Victoria Lopez; Rocio Rojas
Journal:  Allergy Asthma Clin Immunol       Date:  2010-09-16       Impact factor: 3.406

Review 5.  Safety considerations in assessing the role of immunotherapy in allergic disorders.

Authors:  J Bousquet; F B Michel
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 6.  Immunotherapy in fungal allergy.

Authors:  Arthur Helbling; Andrea Reimers
Journal:  Curr Allergy Asthma Rep       Date:  2003-09       Impact factor: 4.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.